Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up

被引:4
作者
Tang, Jiyang [1 ,2 ,3 ,4 ]
Han, Xinyao [1 ,2 ,3 ,4 ]
Tang, Ran [1 ,2 ,3 ,4 ]
Li, Mengyang [1 ,2 ,3 ,4 ]
Wang, Zongyi [1 ,2 ,3 ,4 ]
Zhao, Mingwei [1 ,2 ,3 ,4 ]
Qu, Jinfeng [1 ,2 ,3 ,4 ]
机构
[1] Peking Univ Peoples Hosp, Dept Ophthalmol, 11 Xizhimen South St, Beijing 100044, Peoples R China
[2] Eye Dis & Optometry Inst, Beijing, Peoples R China
[3] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Coll Optometry, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
Pachychoroid; Pachychoroid pigment epitheliopathy; Polypoidal choroidal vasculopathy; Pachychoroid spectrum diseases; NEOVASCULARIZATION; ANGIOGRAPHY;
D O I
10.1186/s12886-022-02487-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Pachychoroid pigment epitheliopathy (PPE), a retinal disorder that falls into the pachychoroid spectrum, is characterized by retinal pigment epithelium changes in pachychoroid eyes without existing or previous subretinal fluid or soft drusen. Previous reports have indicated that PPE may share some pathophysiologic component with other pachychoroid spectrum diseases and could transform into central serous chorioretinopathy (CSC) during follow-up. CSC transformation to PNV and PCV has also been reported, but PPE transformation to PCV has not been reported. Case presentation Seven eyes of seven patients (four male three female, aged 62.7 +/- 8.4 years) who presented with PPE at baseline transformed to PCV during follow-up. All study eyes had baseline contralateral eye diagnoses of PCV. All PPE eyes reported no symptoms at baseline and were followed up regularly for the treatment of their contralateral eyes. All PPE presented as pigment epithelium detachment (PED) at baseline. The mean central macular thickness (CMT) was 217.6 +/- 14.6 mu m, the mean subfoveal choroidal thickness (SFCT) was 354.9 +/- 94.9 mu m, and the mean sub-PPE choroidal thickness was 332.3 +/- 84.6 mu m. The mean PPE width and height were 1326.4 +/- 791.4 mu m and 58.7 +/- 23.6 mu m, respectively, at baseline. Disruption of the ellipsoid zone (EZ) was noted in 3 eyes, while choroidal vascular hyperpermeability (CVH) was noted in 5 eyes at baseline. The follow-up period was 75.0 +/- 41.1 months, and the mean transformation time was 49.6 +/- 24.8 months. All study eyes received no intervention before transformation. Conclusions PPE could transform to PCV after a long follow-up period. Regular follow-ups for a long time should be recommended for patients with PPE.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Five-Year Follow-Up of Unaffected Fellow Eyes in Patients with Polypoidal Choroidal Vasculopathy
    Kim, Kiyoung
    Kim, Jae Min
    Kim, Do Gyun
    Yu, Seung-Young
    Kim, Eung Suk
    OPHTHALMOLOGICA, 2020, 243 (03) : 172 - 177
  • [22] NATURAL COURSE AND FUNDUSCOPIC FINDINGS OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN A JAPANESE POPULATION OVER 1 YEAR OF FOLLOW-UP
    Bessho, Hiroaki
    Honda, Shigeru
    Imai, Hisanori
    Negi, Akira
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (08): : 1598 - 1602
  • [23] INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY A 3-YEAR FOLLOW-UP
    Maruyama-Inoue, Maiko
    Sato, Shimpei
    Yamane, Shin
    Kadonosono, Kazuaki
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (10): : 2001 - 2009
  • [24] Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
    Nemoto, Rei
    Miura, Masahiro
    Iwasaki, Takuya
    Goto, Hiroshi
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1633 - 1638
  • [25] Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy
    Kang, Hyun Goo
    Kang, Hyunseung
    Byeon, Suk Ho
    Kim, Sung Soo
    Koh, Hyoung Jun
    Lee, Sung Chul
    Kim, Min
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 46 (08) : 916 - 925
  • [26] Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy
    Kikushima, Wataru
    Sakurada, Yoichi
    Yoneyama, Seigo
    Sugiyama, Atsushi
    Matsubara, Mio
    Fukuda, Yoshiko
    Kashiwagi, Kenji
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2021, 35
  • [27] Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy
    Aaron Yap
    Nancy Wang
    David Squirrell
    BMC Ophthalmology, 22
  • [28] Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy
    Ramesh Venkatesh
    Santosh Gopi Krishna Gadde
    Arpitha Pereira
    Vivek Singh
    Sajjan Sangai
    Akhila Sridharan
    Bharathi Bavaharan
    Nimesh Jain
    Naresh Kumar Yadav
    International Ophthalmology, 2021, 41 : 87 - 97
  • [29] Impact of sub-foveal choroidal thickness on clinical features and long-term clinical outcomes in polypoidal choroidal vasculopathy
    Venkatesh, Ramesh
    Gadde, Santosh Gopi Krishna
    Pereira, Arpitha
    Singh, Vivek
    Sangai, Sajjan
    Sridharan, Akhila
    Bavaharan, Bharathi
    Jain, Nimesh
    Yadav, Naresh Kumar
    INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (01) : 87 - 97
  • [30] Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy
    Inoue, M.
    Arakawa, A.
    Yamane, S.
    Kadonosono, K.
    EYE, 2013, 27 (09) : 1013 - 1020